Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020089380 - REVERSAL AGENTS FOR NEUTRALIZING THE THERAPEUTIC ACTIVITY OF ANTI-FXIa ANTIBODIES

Publication Number WO/2020/089380
Publication Date 07.05.2020
International Application No. PCT/EP2019/079802
International Filing Date 31.10.2019
IPC
C07K 16/36 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
36against blood coagulation factors
C07K 16/42 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
42against immunoglobulins (anti-idiotypic antibodies)
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 7/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A61P 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
39General protective or antinoxious agents
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 39/39566
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39533against materials from animals
39566against immunoglobulins, e.g. anti-idiotypic antibodies
A61P 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
39General protective or antinoxious agents
A61P 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
C07K 16/36
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
36against blood coagulation factors
C07K 16/4208
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
42against immunoglobulins
4208against an idiotypic determinant on Ig
Applicants
  • BAYER AKTIENGESELLSCHAFT [DE]/[DE]
  • BAYER PHARMA AKTIENGESELLSCHAFT [DE]/[DE]
Inventors
  • WILMEN, Andreas
  • WEBER, Ernst
Agents
  • BIP PATENTS
Priority Data
18203700.231.10.2018EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) REVERSAL AGENTS FOR NEUTRALIZING THE THERAPEUTIC ACTIVITY OF ANTI-FXIa ANTIBODIES
(FR) AGENTS D'INVERSION POUR LA NEUTRALISATION DE L'ACTIVITÉ THÉRAPEUTIQUE D'ANTICORPS ANTI-FXIA
Abstract
(EN)
The present invention relates to reversal agents, which specifically bind to the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D as described in WO2013/167669, and neutralize the therapeutic activity of this anti-FXIa antibody, as well as to compositions comprising these reversal agents. Methods of obtaining the antibodies or antigen-binding fragments thereof (such as Fab fragments) and nucleic acids encoding the same, are also provided. Furthermore, the invention relates to methods of use of these reversal agents, such as methods for neutralizing the therapeutic activity of the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D, and to related methods as essential part of a general bleeding management.
(FR)
La présente invention concerne des agents d'inversion, qui se lient de manière spécifique à l'anticorps anti-FXIa 076D-M007-H04-CDRL3-N110D tel que décrit dans WO2013/167669, et neutralisent l'activité thérapeutique de cet anticorps anti-FXIa, ainsi que des compositions comprenant ces agents d'inversion. L'invention concerne également des procédés d'obtention des anticorps ou des fragments de liaison à l'antigène de ceux-ci (tels que des fragments Fab) et des acides nucléiques codant pour ceux-ci. L'invention concerne en outre des procédés d'utilisation de ces agents d'inversion, tels que des procédés de neutralisation de l'activité thérapeutique de l'anticorps anti-FXIa 076D-M007-H04-CDRL3-N110D, et des procédés associés se rapportant essentiellement à la gestion générale des saignements.
Latest bibliographic data on file with the International Bureau